The Antibacterials Market Outlook to 201610 Jun 2011 • by Natalie Aster
“Despite high patient numbers, the cost and complexities coupled with regulatory uncertainties and challenges have shifted the investment focus of pharmaceutical manufacturers from antibacterials to treatments for chronic conditions.”
The report “The Antibacterials Market Outlook to 2016” by Business Insights provides comprehensive coverage of the global antibacterials market, incorporating disease overview, epidemiological analyses of the major indications, market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading antibacterial brands are assessed and five of the market’s leading players are profiled.
USE THE REPORT TO:
- Assess the forecast epidemiology and development of the antibacterials market across the 7MM;
- Analyze the dynamics of the global antibacterials market and understand the impact of key R&D events, market trends, and issues;
- Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development;
- Predict revenues for major currently marketed and pipeline antibacterial products over 2010–16;
- Develop strategies for success in the future antibacterial market.
ANSWER QUESTIONS LIKE:
- What are the drivers and resistors of the antibacterials market worldwide?
- What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the antibacterials market?
- What is the forecast commercial potential of the most promising compounds in clinical development?
- Who were the leading players in the global antibacterials market in 2010?
- How have recent launches from companies such as GSK, Pfizer, J&J, Novartis and Merck & Co. performed?
Request free sample pages now at: email@example.com
Published: May 2011
Price: US$ 3,835
Of the competing drug classes in global antibacterials market, cephalosporins occupied the leading position with over 25% share followed by penicillins and fluoroquinolones. However, all these drug classes declined in sales in 2010.
Community acquired pneumonia (CAP) and hospital acquired pneumonia (HAP) infections are attracting research interest. Additionally, the majority of companies developing new antibiotics are targeting cell wall synthesis inhibitors, DNA topoisomerase II inhibitors, ribosomal inhibitors and methionine tRNA ligase inhibitors.
To order the report or ask for sample pages contact firstname.lastname@example.org
Tel: +44 208 144 6009
Fax: +44 207 900 3970